POISE -2: Clonidine does not reduce the risk of perioperative death or myocardial infarction in patients undergoing noncardiac surgery

There is some evidence that clonidine administered in small doses for short periods of time prior to noncardiac surgery would be able to prevent cardiac events.This study randomized 10010 patients over 45 years in 135 centers in 23 countries to clonidine or placebo. The primary end point of the study was the rate of death from any cause and nonfatal myocardial infarction at 30 days.At 30 days, the rate of death or infarction observed was 7.3 % in the clonidine group and 6.8 % in the placebo group (p = 0.29). Hypotension or bradycardia clinically important,were more frequent in the clonidine group, hypotension was an independent predictor of infarction (HR 1.37 , P < 0.001).

Conclusion

Clonidine does not reduce the risk of death or myocardial infarction in the perioperative period and should not be administered in patients undergoing noncardiac surgery in order to prevent events.

Article

Loading...

Daniel I. Sessler
2014-03-31

Original title: A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery (POISE-2).

More articles by this author

MSC -HF Trial: Auto mesenchymal cell transplantation may improve ventricular function in patients with heart failure of ischemic cause

This study is a phase 2, randomized 2:1, double blind, and placebo-controlled included 59 patients with advanced heart failure of ischemic etiology undergoing autologous...

ZEUS Trial: Patients with increased risk of bleeding may benefit from eluting stents Zotarolimus

The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients at high risk of bleeding.This study randomized...

NEXT Trial: Biodegradable polymer stent (Nobori) was similar to the permanent polymer stents (Xience / Promus) at 2 years.

This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The...

SIRS Trial: Methylprednisolone does not decrease mortality and increase the risk of stroke in patients undergoing cardiac surgery

Cardiac surgery with cardiopulmonary bypass results in an inflammatory response of the body that is usually associated with adverse outcome. The preventive use of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...